Bhavika Kantilal Patel MD, Presenter: Nothing to Disclose

Karen Drukker PhD, Abstract Co-Author: Royalties, Hologic, Inc

Bonnie N. Joe MD, PhD, Abstract Co-Author: Nothing to Disclose

Dorota Jakubowski Wisner MD, PhD, Abstract Co-Author: Nothing to Disclose

Jennifer S. Drukteinis MD, Abstract Co-Author: Nothing to Disclose

Maryellen L. Giger PhD, Abstract Co-Author: Stockholder, Hologic, Inc Shareholder, Quantitative Insights, Inc Royalties, Hologic, Inc Royalties, General Electric Company Royalties, MEDIAN Technologies Royalties, Riverain Technologies, LLC Royalties, Mitsubishi Corporation Royalties, Toshiba Corporation Researcher, Koninklijke Philips NV Researcher, U-Systems, Inc

Karla Kerlikowske MD, Abstract Co-Author: Nothing to Disclose

Serghei Malkov PhD, Abstract Co-Author: Nothing to Disclose

Malesa M. Pereira BS, Abstract Co-Author: Nothing to Disclose

Leila Kazemi RT, Abstract Co-Author: Nothing to Disclose

Gregor Krings MD, PhD, Abstract Co-Author: Nothing to Disclose

John A. Shepherd PhD, Abstract Co-Author: Nothing to Disclose

Familiarize participants with the novel 3 Compartment Breast (3CB) imaging technique which is based on dual-energy mammography and quantifies the lipid, protein, and water content within the breast. The underlying hypothesis is that 3CB ‘signatures’, i.e., image-based biomarkers, are unique for different lesions types and that knowledge of breast tissue composition improves discrimination between benign and malignant lesions. This could potentially reduce the number of unnecessary breast biopsies and increase their positive predictive value.

• Purpose: To introduce a new quantitative dual energy mammography technique (3CB) for characterizing breast lesions. • Background: o Explanation of 3CB imaging technique as a combination of dual energy mammography with a thickness phantom o Quantification of 3CB ‘signatures’ (lipid, water, and protein) • Potential advantages and disadvantages of 3CB imaging o Advantages: Better specificity, reduced benign biopsy rates, quantitative and reproducible information (water, lipid, protein content of a lesion) o Disadvantages: 10% higher dose than standard digital diagnostic views • Case examples (images and results) o Benign lesions (fibroadenoma, cysts) o Malignant lesions (invasive carcinoma, DCIS) o High risk lesions (atypia) • Description of ongoing clinical trials and future plans

http://abstract.rsna.org/uploads/2014/14007306/14007306_mzue.pdf

Patel, B, Drukker, K, Joe, B, Wisner, D, Drukteinis, J, Giger, M, Kerlikowske, K, Malkov, S, Pereira, M, Kazemi, L, Krings, G, Shepherd, J, An Introduction to the Novel 3 Compartment Breast (3CB) Imaging Technique.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14007306.html